---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053934"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:20:42.268654+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon raises $50M in oversubscribed private placement; tegoprubart advances in transplant trials

## Summary
- Gross proceeds ~$50M from 13.1M shares at $2.37/sh and 7.99M pre-funded warrants at $0.001/sh.
- Financing led by BVF Partners; expected to close week of May 6; net proceeds for pre-commercial activities and tegoprubart development.
- First participant dosed in islet cell transplant trial with tegoprubart for type 1 diabetes at University of Chicago.
- Updated Phase 1b kidney transplant data: mean eGFR >60 mL/min after day 30; two subjects at 12 months had eGFR >90.
- No graft loss or death in Phase 1b; three discontinuations (hair loss/fatigue, viral infection, rejection).

## SEC filing metadata
- accession: 0000950170-24-053934
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/0000950170-24-053934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053934
- JSON: https://secwatch.observer/filing/0000950170-24-053934.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053934.txt

## Key facts
- Material Agreements
  Eledon Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors (the "Purchasers") valued at approximately $50 million (effective 2024-05-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors (the "Purchasers")
  - Value: approximately $50 million
  - Effective: 2024-05-06
  source text: On May 6, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 13,110,484 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) at a price of $2.37 per share, and pre-funded warrants (the “Pre-Funded Warrants”) at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/0000950170-24-053934-index.htm
- Material Agreements
  Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-05-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Effective: 2024-05-06
  source text: In connection with the Private Placement, the Company entered into a registration rights agreement, dated May 6, 2024 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/0000950170-24-053934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.